PHA-767491

PHA-767491 is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.

Product Specifications

CAS Number

845714-00-3

Product Name Alternative

CAY10572

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pha-767491.html

Purity

99.97

Solubility

DMSO : 15.38 mg/mL (ultrasonic; adjust pH to 2 with 1 M HCL)

Smiles

O=C1C2=C(NC(C3=CC=NC=C3)=C2)CCN1

Molecular Formula

C12H11N3O

Molecular Weight

213.24

Precautions

H315, H319, H320

References & Citations

[1]Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9 (11) :e113300.|[2]Li W, et al. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15 (3) :196-204.|[3]Erbayraktar Z, et al. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int. 2016 Nov 18;16:88.|[4]Montagnoli A, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4 (6) :357-65.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

CDK1; CDK2; CDK5; CDK9

Citation 01

Acta Pharmacol Sin. 2022 Apr;43 (4) :1033-1045.|Nat Commun. 2024 Dec 5;15 (1) :10594.|Autophagy. 2022 Aug;18 (8) :1879-1897.|Sci Rep. 2021 Mar 8;11 (1) :5374.